Hemolytic Disease of the Fetus and Newborn clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
open to eligible females ages 18-45
The purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood cell volume falls below normal levels while the baby is developing in…
at UC Davis
Last updated: